# EDGAR Filing Document

**Accession Number:** 0002040475
**File Stem:** 0000000000-25-009970
**Filing Date:** 2025-9
**Character Count:** 4446
**Document Hash:** 46de89d8a719e047254e0efa45ea0d26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009970.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0000000000-25-009970

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250915

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II Corp.
- **CENTRAL INDEX KEY:** 0002040475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07803

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-025159

## Text-Extract

```

                                                            September 15, 2025

Lynn Stockwell
Chief Executive Officer
Drugs Made In America Acquisition II Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301

       Re: Drugs Made In America Acquisition II Corp.
           Amendment No. 2 to Registration Statement on Form S-1
           Filed September 15, 2025
           File No. 333-288791
Dear Lynn Stockwell:

     We have reviewed your amended registration statement and have the
following
comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Amendment No. 2 to Registration Statement on Form S-1
General

1.     We note your revised disclosure regarding the transfer of founder shares
to certain
       accredited investors unaffiliated with your sponsor on page 137. Please
reconcile
       these transfers with the terms set forth in the letter agreement filed
as exhibit 10.3,
       including transfer restrictions. Clarify whether your "initial
shareholders" as
       referenced in the prospectus on page 14 is intended to include these
investors and the
       "founder shares" are intended to include such transferred shares, or
revise your
       disclosure throughout your prospectus regarding your initial
shareholders and the
       founder shares accordingly, including, for example, where you state that
your initial
       shareholders will own 20% of your issued and outstanding shares after
this offering.
       Please clarify whether such investors will be parties to or otherwise
subject to the
       lock-up and other provisions in the letter agreement and the
underwriting agreement
 September 15, 2025
Page 2

       and revise your disclosure in the summary on page 7 and elsewhere to
clarify which
       holders of founder shares are subject to such restrictions, and file
updated exhibits as
       appropriate. In this regard, we note that on page 7, you state that the
initial
       shareholders and founder shares are subject to transfer restrictions,
but these
       transferees do not appear to be signatories of the letter agreement
filed as Exhibit
       10.3. Also, tell us if such investors in the founder shares were to
purchase shares
       from public shareholders, whether such purchases would by structured in
compliance
       with the requirements of Rule 14e-5 under the Exchange Act.
       Please contact Babette Cooper at 202-551-3396 or Isaac Esquivel at
202-551-3395 if
you have questions regarding comments on the financial statements and related
matters. Please contact Ruairi Regan at 202-551-3269 or Dorrie Yale at
202-551-8776 with
any other questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Real
Estate & Construction
cc:   Alex Weniger-Araujo, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._